Effect of natriuretic peptide–guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 318, Issue 8, 2017, Pages 713-720

  Felker, G Michael ^a   Anstrom, Kevin J ^a   Adams, Kirkwood F ^b   Ezekowitz, Justin A ^c   Fiuzat, Mona ^a   Houston Miller, Nancy ^d   Januzzi, James L ^e   Mark, Daniel B ^a   Piña, Ileana L ^f   Passmore, Gayle ^a   Whellan, David J ^g   Yang, Hongqiu ^a   Cooper, Lawton S ^h   Leifer, Eric S ^h   Desvigne Nickens, Patrice ^h   O’Connor, Christopher M ^a,i  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d LifeCare Company   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

ⁱ Inova Heart and Vascular Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ADVERSE OUTCOME; ARTICLE; BRADYCARDIA; CANADA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; UNITED STATES; AGED; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; HOSPITALIZATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SINGLE-BLIND METHOD; STROKE VOLUME; TREATMENT FAILURE; VENTRICULAR DYSFUNCTION;

EID: 85028365288     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.10565     Document Type: Article

References (20)

1. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294(10):1240-1247.
2. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585-596.
3. Januzzi JL Jr, Sakhuja R, O’donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315-320.
4. Anand IS, Fisher LD, Chiang YT, et al. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278-1283.
5. Masson S, Latini R, Anand IS, et al. Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997-1003.
6. Eurlings LWM, van Pol PEJ, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090-2100.
7. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126-1130.
8. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58(18):1881-1889.
9. Pfisterer M, Buser P, Rickli H, et al. TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-392.
10. Berger R, Moertl D, Peter S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55(7):645-653.
11. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53-60.
12. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422-430.
13. Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35(23): 1559-1567.
14. Yancy CW, Jessup M, Bozkurt B, et al. WRITING COMMITTEE MEMBERS; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16): e240-e327.
15. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200.
16. Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. JACC Heart Fail. 2014;2(5):457-465.
17. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
18. Bang H, Tsiatis A. Estimating medical costs with censored data. Biometrika. 2000;87:329-343.
19. Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100-1120.
20. Felker GM, Whellan D, Kraus WE, et al. HF-ACTION Investigators. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. Am Heart J. 2009;158 (4)(suppl):S37-S44.